Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial of Intravitreous Aflibercept Versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema

NCT03321513 is registered in ClinicalTrials.gov with Jaeb Center for Health Research as lead sponsor.

NCT NCT03321513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03321513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial of Intravitreous Aflibercept Versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema
Lead sponsor
Jaeb Center for Health Research
Phase
Phase 3
Overall status
Completed
Start date
December 7, 2017
Completion date
December 22, 2021
Enrollment
270 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema